Bayer Logo

This promotional animation has been commissioned by Bayer plc and developed in partnership with Guidelines. Please see the bottom of the page for the full disclaimer.

View Xarelto (rivaroxaban) prescribing information and adverse event reporting

 

Dr Matthew Fay discusses the changes to the NICE atrial fibrillation (AF) guideline (NG196),1  highlighting the preferential use of direct-acting oral anticoagulants (DOACS) in patients with non-valvular atrial fibrillation and the importance of shared decision making.

This animation covers:

  • prevalence and diagnosis of AF
  • how to assess stroke and bleeding risk in patients using the CHA2 DS2‑VASc score for stroke risk and the ORBIT score for bleeding risk
  • NICE recommendations when deciding between anticoagulation treatment options
  • shared decision making
  • how to transition from warfarin to Xarelto.

 

Reference:

  1. NICE. Atrial fibrillation: diagnosis and management. NICE guideline 196. NICE, 2021. Available at: www.nice.org.uk/guidance/NG196

This promotional animation has been commissioned by Bayer plc and developed in partnership with Guidelines. Bayer plc suggested the topic and presenter, and carried out full medical approval on all materials to ensure compliance with regulations. The presenter was paid an honorarium by Bayer plc. The views and opinions expressed in the animation are not necessarily those of Guidelines, its publisher, advisers, or advertisers. No part of this animation may be reproduced in any form without the permission of the publisher.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc. Tel.: 0118 206 3500, Fax.: 0118 206 3703, Email: pvuk@bayer.com  

 

PP-XAR-GB-2153

Date of preparation: December 2021